Skip to main contentSkip to navigation
Sirius Investors
Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc.

YMAB
NASDAQHealthcare

Y-mAbs Therapeutics, Inc. (YMAB) Investment Research Dashboard

About Y-mAbs Therapeutics, Inc. (YMAB) stock analysis

Get live YMAB stock price $8.61, comprehensive Y-mAbs Therapeutics, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time YMAB stock data and investment insights.

8.61
0.23%Today
Market Cap
391.22M
Volume
760.67K
52W High
16.11
52W Low
3.55

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship pro...

Company Information

CEO
Michael Rossi
Sector
Healthcare
Industry
Biotechnology
Employees
104

Contact Information

Address
230 Park Avenue
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.53) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Y-mAbs Therapeutics, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Y-mAbs Therapeutics, Inc.
  • Investors should consider how Y-mAbs Therapeutics, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

391.22M

P/E Ratio (TTM)

-17.22

Beta

0.53

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

78/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
78/100⭐⭐⭐⭐⭐
Communication Services+1.4%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.8%+0.7%29.7
64/100⭐⭐⭐⭐
Basic Materials+0.4%+1.2%-0.2%25.2
61/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.5%29.2
43/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
37/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
23/100
Consumer Cyclical+0.5%-1.5%-5.8%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.